Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

被引:227
作者
Tydén, G [1 ]
Kumlien, G
Fehrman, I
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Transplantat Surg, S-14186 Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Dept Transfus Med, S-14186 Stockholm, Sweden
[3] Huddinge Univ Hosp, Karolinska Inst, Dept Renal Med, S-14186 Stockholm, Sweden
关键词
D O I
10.1097/01.TP.0000078622.43689.D4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Historically, ABO-incompatible kidney transplantations have only been undertaken after splenectomy and unspecific plasmapheresis and with quadruple drug immunosuppression plus B-cell specific drugs. We have evaluated a protocol for ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption, rituximab, and a conventional triple-drug immunosuppressive regimen. Methods. The protocol called for a 10-day pretransplant conditioning period starting with one dosage of rituximab and followed by full dose tacrolimus, mycophenolate mofetil, and prednisolone. Antigen-specific immunoadsorption was performed on pretransplant days - 6, - 5, - 4, and - 1. After the last session, 0.5 g/kg of intravenous immunoglobulin was administered. Postoperatively, three more apheresis sessions were given every third day. Furthermore, if there was a significant increase in the antibody titers, extra sessions were considered. Results. Four patients have received transplants with this protocol. The donor-recipient blood groups were A2/O, B/O, B/A, and A1/O. The ABO-antibodies were readily removed by the antigen-specific immunoadsorption and were kept at a low level posttransplantation by further adsorptions. There were no side effects, and all patients have normal renal-transplant function. Conclusions. We conclude that after one infusion each of rituximab and intravenous immunoglobulin and antigen-specific immunoadsorption, blood-group-incompatible renal transplantations can be performed with standard immunosuppression and without splenectomy.
引用
收藏
页码:730 / 731
页数:2
相关论文
共 5 条
  • [1] Rituximab: mechanisms and applications
    Johnson, PWM
    Glennie, MJ
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (11) : 1619 - 1623
  • [2] Nelson PW, 1998, TRANSPLANTATION, V65, P256
  • [3] ABO-incompatibility in solid organ transplantation
    Rydberg, L
    [J]. TRANSFUSION MEDICINE, 2001, 11 (04) : 325 - 342
  • [4] Transplantation of ABO group A2 kidneys from living donors into group O and B Recipients
    Sorensen, JB
    Grant, WJ
    Belnap, LP
    Stinson, J
    Fuller, TC
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (03) : 296 - 299
  • [5] TOMA H, 1994, UROL CLIN N AM, V21, P299